Alvespimycin (TFA)
Alvespimycin (17-DMAG) TFA is a potent inhibitor of Hsp90, binding to Hsp90 with an EC50 of 62 nM[1].
Product Specifications
Product Name Alternative
17-DMAG (TFA) ; KOS-1022 (TFA) ; NSC 707545 (TFA)
UNSPSC
12352211
Hazard Statement
H315, H319, H335
Target
HSP
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
98.97
Smiles
O=C(O)C(F)(F)F.C/C1=C\C=C/[C@@H]([C@H](/C(C)=C/[C@@H]([C@H]([C@H](C[C@@H](CC(C(C(NC1=O)=CC2=O)=O)=C2NCCN(C)C)C)OC)O[H])C)OC(N)=O)OC
Molecular Formula
C34H49F3N4O10
Molecular Weight
730.77
Precautions
H315, H319, H335
References & Citations
[1]Ge J, et al. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem. 2006 Jul 27;49 (15) :4606-15.|[2]Hertlein E, et al. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood. 2010 Jul 8;116 (1) :45-53.|[3]Henke A, et al. Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90. Cancers (Basel) . 2016 Aug 24;8 (9) . pii: E77.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC401219-100 1x 100 µL
Cytokeratin 8 (B22.1), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 